Board Change • May 20
High number of new directors Independent Director Cecilia Lager was the last director to join the board, commencing their role in 2025. Annuncio • Apr 28
Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million. Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million on April 27, 2026. A cash consideration will be paid by Carasent AB (publ). The purchase price will be paid 90 percent in cash and 10 percent in already repurchased Carasent shares, valued at SEK 23.74 per share based on a 90-day volume-weighted average price (VWAP), corresponding to 538,555 shares.
For the period ending December 31, 2025, Infosolutions Sverige Ab reported total revenue of SEK 67 million.
The expected completion of the transaction is April 27, 2026 to June 30, 2026. Annuncio • Feb 09
Carasent AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026 Carasent AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 12, 2026 Annuncio • Dec 17
Carasent AB (publ) (OM:CARA) announces an Equity Buyback for 10% of its issued share capital. Carasent ASA (OB:CARA) commences share repurchases on December 16, 2025, under the program mandated by shareholders in the Annual General Meeting held on April 23, 2025. As per the mandate, the company is authorized to repurchase up to 10% of its issued share capital, such that the company’s holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital at any point of time. The purpose of the program is transfer of shares may be made with deviation from shareholders' preferential rights is to enable financing of acquisitions.
On July 9, 2025, the company initiated a Market repurchases. Under the program, the company will repurchase up to SEK 150 million worth of its shares. The payment for acquired shares shall be made in cash. The repurchases may last until the 2026 Annual General Meeting at the latest. Annuncio • Oct 23
Carasent AB (publ), Annual General Meeting, Apr 20, 2026 Carasent AB (publ), Annual General Meeting, Apr 20, 2026. Location: stockholm Sweden Annuncio • Oct 10
Carasent AB (publ) to Report Q3, 2025 Results on Oct 16, 2025 Carasent AB (publ) announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 16, 2025 Annuncio • Jul 08
Carasent AB (publ) to Report Q2, 2025 Results on Jul 10, 2025 Carasent AB (publ) announced that they will report Q2, 2025 results at 7:00 AM, Central European Standard Time on Jul 10, 2025 Annuncio • Apr 24
Carasent AB (Publ) Announces Board Appointments Carasent AB (publ) at its Annual General Meeting on 23 April 2025, approved to elect Johan Kallblad, Dr. Carol Wildhagen and Cecilia Lager as new Board members, and to elect Tomas Meerits as the Chairman of the Board. Annuncio • Apr 08
Carasent AB (publ) to Report Q1, 2025 Results on Apr 11, 2025 Carasent AB (publ) announced that they will report Q1, 2025 results at 7:00 AM, Central European Standard Time on Apr 11, 2025 Annuncio • Feb 24
Carasent AB (publ), Annual General Meeting, Apr 23, 2025 Carasent AB (publ), Annual General Meeting, Apr 23, 2025. Annuncio • Oct 29
Carasent ASA (OB:CARA) acquired Data - Al GmbH. Carasent ASA (OB:CARA) acquired Data - Al GmbH on October 28, 2024. The transaction values DataAl at an enterprise value of €8 million, with potential additional earnout payments of up to €4 million pending future growth. Data - Al has reported revenues of approximately €4 million and EBITDA of approximately €0.5 million in 2023.
Carasent ASA (OB:CARA) completed the acquisition of Data - Al GmbH on October 28, 2024. Reported Earnings • Oct 25
Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023) Third quarter 2024 results: kr0.03 loss per share (improved from kr0.06 loss in 3Q 2023). Revenue: kr66.3m (up 19% from 3Q 2023). Net loss: kr2.03m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. New Risk • Sep 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Board Change • Jul 30
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • May 01
Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion. Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion on April 4, 2024. Offer price per share is NOK 20. The transaction is subject to subject to customary conditions, including acceptance level and any regulatory approvals required. The Offer has already received strong support from key shareholders representing 34% of the share capital of Carasent. Launch of the Offer is subject to, inter alia, a customary confirmatory due diligence of key commercial, financial, technical and legal aspects of Carasent with a focus on confirming key assumptions. The board of directors advises all shareholders to monitor the situation but not take any action in respect of the offer which may be made by EG until shareholders can assess the merits of such offer on the basis of further developments. DNB Markets acted as financial advisor and Advokatfirmaet BAHR AS acted as legal advisor to Carasent. Carnegie AS acted as financial advisor and Arntzen de Besche acted as legal advisor to Eg Norge. Reported Earnings • Apr 26
First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023) First quarter 2024 results: kr0.15 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr66.9m (up 12% from 1Q 2023). Net loss: kr10.6m (loss widened kr9.52m from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Annuncio • Apr 20
Carasent ASA Announces Changes to Its Board Carasent ASA, at its Annual General Meeting held on April 17, 2024, approved the following. In accordance with the proposal from the Company's Nomination Committee, Henric Carlsson elected as a new Director for a period of two years, cf. the Public Limited Liability Companies Act § 6-6. The new Board of Directors consists of: Petri Niemi, Chairman; Camilla Skoog; Ulrika Cederskog Sundling; Tomas Meerits; Henric Carlsson. In accordance with the proposal from the Company's Board of Directors and Nomination Committee, Jesper Jannerberg and Peder Strand elected as new members of the Committee for a period of two years. Reported Earnings • Mar 25
Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022) Full year 2023 results: kr0.60 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Feb 26
Chief Executive Officer recently bought €121k worth of stock On the 23rd of February, Daniel Ohman bought around 135k shares on-market at roughly €0.89 per share. This transaction increased Daniel's direct individual holding by 5x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €2.4m. Daniel has been a buyer over the last 12 months, purchasing a net total of €137k worth in shares. Reported Earnings • Feb 16
Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022) Full year 2023 results: kr0.64 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Feb 01
Founder recently bought €2.4m worth of stock On the 30th of January, Niclas Hugosson bought around 3m shares on-market at roughly €0.95 per share. This transaction increased Niclas' direct individual holding by 552x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Niclas has been a buyer over the last 12 months, purchasing a net total of €2.0m worth in shares. Board Change • Jan 07
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. New Risk • Dec 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 1.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (€68.9m market cap, or US$75.0m). Annuncio • Nov 30
Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors Carasent ASA announced that Board member Staffan Hanstorp has given notice of his resignation as a member of the board of directors of Carasent ASA with immediate effect. Annuncio • Nov 16
Carasent Asa Approves Dividend Carasent ASA approved dividend of NOK 1.84 per share, totaling NOK 133,077,597 million. The payment is to be based on the approved 2022 Annual Accounts. Reported Earnings • Jul 16
Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022) Second quarter 2023 results: kr0.64 loss per share (down from kr0.03 profit in 2Q 2022). Revenue: kr63.2m (up 36% from 2Q 2022). Net loss: kr51.3m (down kr53.7m from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • May 05
First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022) First quarter 2023 results: kr0.01 loss per share (down from kr0.32 profit in 1Q 2022). Revenue: kr59.9m (up 34% from 1Q 2022). Net loss: kr1.04m (down 104% from profit in 1Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Apr 06
Full year 2022 earnings released Full year 2022 results: Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Feb 16
Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021) Full year 2022 results: EPS: kr0.39 (up from kr0.002 loss in FY 2021). Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. 1 highly experienced director. Independent Chairman of the Board Johan Lindqvist is the most experienced director on the board, commencing their role in 2007. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improved over the past week After last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 91x. Average forward P/E is 27x in the Healthcare Services industry in Europe. Total loss to shareholders of 60% over the past year. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021) Third quarter 2022 results: EPS: kr0.13 (up from kr0.28 loss in 3Q 2021). Revenue: kr47.4m (up 28% from 3Q 2021). Net income: kr10.4m (up kr31.8m from 3Q 2021). Profit margin: 22% (up from net loss in 3Q 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Jul 16
Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021) Second quarter 2022 results: EPS: kr0.03 (down from kr0.34 in 2Q 2021). Net income: kr2.40m (down 88% from 2Q 2021). Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 19% share price gain to €2.07, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 29x in the Healthcare Services industry in Europe. Total loss to shareholders of 40% over the past year. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021) First quarter 2022 results: EPS: kr0.32 (up from kr0.14 loss in 1Q 2021). Revenue: kr44.8m (up 59% from 1Q 2021). Net income: kr25.4m (up kr33.1m from 1Q 2021). Profit margin: 57% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 41%, compared to a 26% growth forecast for the industry in Germany. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Staffan Hanstorp was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 04
Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020) Full year 2021 results: kr0.002 loss per share (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net loss: kr148.0k (loss narrowed 100% from FY 2020). Over the next year, revenue is forecast to grow 53%, compared to a 31% growth forecast for the industry in Germany. Reported Earnings • Feb 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr0.01 (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net income: kr642.0k (up kr38.8m from FY 2020). Profit margin: 0.5% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 44% growth forecast for the industry in Germany. Reported Earnings • Oct 28
Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020) The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr36.9m (up 109% from 3Q 2020). Net loss: kr21.4m (loss widened 136% from 3Q 2020). Reported Earnings • Aug 21
Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr32.0m (up 88% from 2Q 2020). Net income: kr19.9m (up kr25.5m from 2Q 2020). Profit margin: 62% (up from net loss in 2Q 2020). Executive Departure • Aug 04
Chief Financial Officer Lars Forsberg has left the company On the 1st of August, Lars Forsberg's tenure as Chief Financial Officer ended. We don't have any record of a personal shareholding under Lars' name. A total of 2 executives have left over the last 12 months. Reported Earnings • May 01
First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr28.2m (up 81% from 1Q 2020). Net loss: kr7.67m (down kr8.06m from profit in 1Q 2020). Reported Earnings • Mar 29
Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019) The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr70.6m (up 47% from FY 2019). Net loss: kr38.1m (down kr41.3m from profit in FY 2019). Annuncio • Mar 04
Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA). Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA) on March 2, 2021. As a part of the transaction Aeternum Capital acquired 8.25 million shares.
Aeternum Capital AS, a fund managed by Aeternum Management AS completed the acquisition of 15% stake in Carasent ASA (OB:CARA) on March 2, 2021. Analyst Estimate Surprise Post Earnings • Feb 18
Revenue misses expectations Revenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 36%, compared to a 21% growth forecast for the Healthcare Services industry in Germany. Is New 90 Day High Low • Feb 16
New 90-day high: €3.76 The company is up 66% from its price of €2.27 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 7.0% over the same period. Is New 90 Day High Low • Dec 23
New 90-day high: €3.42 The company is up 46% from its price of €2.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period. Annuncio • Dec 12
Carasent ASA Appoints Dennis Höjer as CEO The Board of Directors of Carasent ASA announced that it has appointed Dennis Höjer as new CEO. Dennis is currently CEO of Evimeria EMR AB and COO of Carasent ASA and will assume his new position January 1, 2021. Dennis Höjer, 33, is currently CEO of Evimeria EMR AB and COO of Carasent ASA, a position which he has held since 2018. Prior to 2018 Dennis had several different roles in Evimeria related to sales and marketing and he has been within the group since 2013. Is New 90 Day High Low • Dec 02
New 90-day high: €2.59 The company is up 12% from its price of €2.31 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total losses of kr14.4m, with earnings decreasing by kr16.0m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total losses of kr14.0m, with earnings decreasing by kr15.1m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year.